Show simple item record

dc.contributor.authorHossain, Faria
dc.contributor.authorPicado, Albert
dc.contributor.authorOwen, Sophie I
dc.contributor.authorGhosh, Prakash
dc.contributor.authorChowdhury, Rajashree
dc.contributor.authorMaruf, Shomik
dc.contributor.authorKhan, Md Anik Ashfaq
dc.contributor.authorRashid, Md Utba
dc.contributor.authorNath, Rupen
dc.contributor.authorBaker, James
dc.contributor.authorGhosh, Debashis
dc.contributor.authorAdams, Emily R
dc.contributor.authorDuthie, Malcolm S
dc.contributor.authorHossain, Md Sakhawat
dc.contributor.authorBasher, Ariful
dc.contributor.authorNath, Proggananda
dc.contributor.authorAktar, Fatima
dc.contributor.authorCruz, Israel 
dc.contributor.authorMondal, Dinesh
dc.date.accessioned2021-05-23T17:41:41Z
dc.date.available2021-05-23T17:41:41Z
dc.date.issued2021
dc.identifier.citationFront Cell Infect Microbiol . 2021 Apr 26;11:670759.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/12997
dc.description.abstractWith reduced prevalence of visceral leishmaniasis (VL) in the Indian subcontinent (ISC), direct and field deployable diagnostic tests are needed to implement an effective diagnostic and surveillance algorithm for post-elimination VL control. In this regard, here we investigated the diagnostic efficacies of a loop-mediated isothermal amplification (LAMP) assay (Loopamp™ Leishmania Detection Kit, Eiken Chemical CO., Ltd, Japan), a real-time quantitative PCR assay (qPCR) and the Leishmania antigen ELISA (CLIN-TECH, UK) with different sampling techniques and evaluated their prospect to incorporate into post-elimination VL control strategies. Eighty clinically and rK39 rapid diagnostic test confirmed VL cases and 80 endemic healthy controls were enrolled in the study. Peripheral blood and dried blood spots (DBS) were collected from all the participants at the time of diagnosis. DNA was extracted from whole blood (WB) and DBS via silica columns (QIAGEN) and boil & spin (B&S) methods and tested with qPCR and Loopamp. Urine was collected from all participants at the time of diagnosis and was directly subjected to the Leishmania antigen ELISA. 41 patients were followed up and urine samples were collected at day 30 and day 180 after treatment and ELISA was performed. The sensitivities of the Loopamp-WB(B&S) and Loopamp-WB(QIA) were 96.2% (95% CI 89·43-99·22) and 95% (95% CI 87·69-98·62) respectively. The sensitivity of Loopamp-DBS(QIA) was 85% (95% CI 75·26- 92·00). The sensitivities of the qPCR-WB(QIA) and qPCR-DBS(QIA) were 93.8% (95% CI 86·01-97·94) and 72.5% (95% CI 61·38-81·90) respectively. The specificity of all molecular assays was 100%. The sensitivity and specificity of the Leishmania antigen ELISA were 97.5% (95% CI 91·47-99·70) and 91.95% (95% CI 84·12-96·70) respectively. The Leishmania antigen ELISA depicted clinical cure at day 180 in all the followed-up cases. Efficacy and sustainability identify the Loopamp-WB(B&S) and the Leishmania antigen ELISA as promising and minimally invasive VL diagnostic tools to support VL diagnostic and surveillance activities respectively in the post-elimination era.es_ES
dc.description.sponsorshipThis work was largely supported by funds from the Federal Ministry of Education and Research, Germany (KfW grant reference number 202060457, Development of Products for the Prevention, Diagnosis and Treatment of Neglected and Poverty Related Diseases; https://www.bmbf.de/en), Wellcome Trust Seed funding (grant no. 108080/Z/15/Z) and the MRC-DTP (grant no. MR/N013514/1). UK aid from the UK Government, the Government of Switzerland and the Government of Netherlands also contributed to FIND’s participation in this work.es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Mediaes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectLAMPes_ES
dc.subjectDiagnosises_ES
dc.subjectDiagnostics for VL post-elimination eraes_ES
dc.subjectEliminationes_ES
dc.subjectQPCRes_ES
dc.subjectUrine ELISAes_ES
dc.subjectVisceral leishmaniasises_ES
dc.titleEvaluation of Loopamp™ Leishmania Detection Kit and Leishmania Antigen ELISA for Post-Elimination Detection and Management of Visceral Leishmaniasis in Bangladesh.es_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID33981632es_ES
dc.format.volume11es_ES
dc.format.page670759es_ES
dc.identifier.doi10.3389/fcimb.2021.670759es_ES
dc.contributor.funderFederal Ministry of Education and Research (Germany)
dc.contributor.funderWellcome Trust
dc.contributor.funderGovernment of the United Kingdom
dc.contributor.funderGovernment of Switzerland
dc.contributor.funderGovernment of Netherlands
dc.description.peerreviewedes_ES
dc.identifier.e-issn2235-2988es_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fcimb.2021.670759es_ES
dc.identifier.journalFrontiers in Cellular and Infection Microbiologyes_ES
dc.repisalud.centroISCIII::Escuela Nacional de Sanidades_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional